Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Gilead helped develop remdesivir, an IV coronavirus treatment, with federal funding. Photo: Josh Edelson/AFP via Getty Images

Thirty-four state and territory attorneys general sent a letter today to federal health agencies asking the federal government to exercise march-in drug rights for remdesivir as a way "to help increase the supply of this drug and lower the price so it is accessible to our state residents."

The big picture: March-in rights — which would allow a patented drug developed with federal dollars to be licensed out to third parties — have never been exercised before. Gilead Sciences, the manufacturer and patent holder of remdesivir, did not immediately respond to requests for comment.

Go deeper

Nov 11, 2020 - Health

EU purchases 200 million doses of Pfizer's COVID-19 vaccine

Illustration: Sarah Grillo/Axios

The European Union struck a deal with Pfizer and BioNTech to buy at least 200 million doses of their coronavirus vaccine in the largest initial order to date, the companies announced Wednesday.

Driving the news: Pharmaceutical giant Pfizer announced Monday that its coronavirus vaccine trial was effective in preventing COVID-19 infections in 90% of previously uninfected people and did not produce any serious safety concerns.

White House urges Iowa to tighten restrictions as COVID-19 surges

Reynolds meets with Trump in May. Photo: Saul Loeb/AFP via Getty Images

Iowa is experiencing an "unyielding COVID spread," illustrated by swelling hospital admissions and ICU data, according to a Nov. 8 White House Coronavirus Task Force report obtained by the local ABC News affiliate.

Driving the news: Iowa Gov. Kim Reynolds, who has repeatedly said that strict rules were unnecessary and ineffective, on Tuesday issued limits on large gatherings and implemented a partial mask mandate for social settings and some businesses.

Updated 14 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: Pfizer coronavirus vaccine safe, effective in children, company says — The COVID booster vaccine discussion is far from over — Cuba becomes first country to begin mass vaccination of children.
  2. Health: Chicago has highest COVID-19 case rates in city worker neighborhoods — International Mission Board to require COVID vaccine for missionaries.
  3. Politics: Biden administration to lift travel ban for fully vaccinated international travelers — Footage shows new details after NYC restaurant incident over proof of vaccination.
  4. Education: More schools using "test-to-stay" strategy to minimize quarantines — Most Kentucky school boards vote in favor of mask mandates —Denver looks to students to close Latino vaccination gap.
  5. Variant tracker: Where different strains are spreading.